CAD106

BIOLOGICAL6 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Alzheimer DiseaseAlzheimer's Disease

Phase 1

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

CompletedNCT00411580

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2005-06-30End: 2008-12-31Updated: 2013-03-29

Phase 2

Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

CompletedNCT00733863

NovartisAlzheimer Disease

Start: 2008-07-31Updated: 2020-02-11

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

CompletedNCT00795418

NovartisAlzheimer's Disease

Start: 2008-10-31Updated: 2020-12-17

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

CompletedNCT00956410

NovartisAlzheimer Disease

Start: 2009-09-30End: 2011-06-30Updated: 2020-02-11

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

CompletedNCT01023685

NovartisAlzheimer Disease

Start: 2009-12-31End: 2012-02-29Updated: 2020-12-17

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

CompletedNCT01097096

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2010-03-31End: 2012-12-31Updated: 2021-03-05

Related Papers

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.

2015-04-2799 citations

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

2012-06-06217 citations